Sham controls are used when blinding is feasible (e.g., neurostimulator off-state, sham endoscopic procedures) and ethical, providing the strongest control against placebo effects. A sham procedure imitates the experience of treatment without the active element, for example an inactive stimulation or a procedure without the therapeutic step. Because shams can carry procedural risk, ethics committees weigh their justification closely. Renal denervation trials are a well known example where sham-controlled designs changed conclusions reached in earlier open-label studies.

Why it matters

Sham-controlled device trials raise ethics, IRB, and patient acceptance challenges; FDA has issued specific guidance on appropriate use.

Common pitfalls

•Sham controls must be ethically justifiable, ensuring that withholding the active treatment does not pose undue risk to participants.
•Designing an effective sham control requires careful consideration to ensure it truly mimics the active intervention without providing therapeutic benefit.
•Patient recruitment can be challenging in trials utilizing sham controls due to the potential for participants to receive a non-therapeutic intervention.
•Failing to adequately blind participants or investigators to the sham control can introduce bias and compromise the study results.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.